Want to see HK:2877 full AI Analyst Report?
Top Page
China Shineway Pharmaceutical Group Limited
(2877)
Select Model
Select Model
Rating:77Outperform
Price Target:
HK$9.00
â–²(5.63% Upside)
Action:Reiterated
Date:08/06/26
Overall score reflects strong fundamentals (especially the very conservative balance sheet and high profitability) and compelling valuation (low P/E and high dividend yield), partially offset by weak technical trend and subdued momentum indicators.
Positive Factors
Very Conservative Balance Sheet
Minimal leverage limits financial risk and interest burdens, while the substantial equity base supports resilience. Solid ROE indicates the company generates reasonable shareholder returns without depending heavily on borrowing.
Negative Factors
Revenue Contraction
Sustained revenue weakness signals softer demand, reduced prescription or healthcare-channel activity, or unfavorable product mix. Without a clear growth catalyst, lower sales can constrain operating leverage and weaken the longer-term earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Conservative Balance Sheet
Minimal leverage limits financial risk and interest burdens, while the substantial equity base supports resilience. Solid ROE indicates the company generates reasonable shareholder returns without depending heavily on borrowing.
Read all positive factors
China Shineway Pharmaceutical Group Limited (2877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.19B
Dividend Yield16.92%
Average Volume (3M)905.49K
Price to Earnings (P/E)6.8
Beta (1Y)0.53
Revenue Growth-17.74%
EPS Growth1.12%
CountryHK
Employees2,822
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.25
Shares Outstanding827,000,000
10 Day Avg. Volume1,875,899
30 Day Avg. Volume905,489
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.72
Price to Sales (P/S)1.86
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$3.03B
China Shineway Pharmaceutical Group Limited Business Overview & Revenue Model
Company Description
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product ...
How the Company Makes Money
null...
China Shineway Pharmaceutical Group Limited Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
90
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.14B | 3.78B | 4.52B | 3.95B | 3.22B |
| Gross Profit | 2.27B | 2.83B | 3.39B | 2.94B | 2.41B |
| EBITDA | 739.52M | 1.00B | 1.42B | 1.10B | 903.74M |
| Net Income | 949.95M | 840.05M | 969.51M | 722.77M | 556.67M |
Balance Sheet | |||||
| Total Assets | 10.78B | 10.04B | 9.57B | 8.23B | 7.20B |
| Cash, Cash Equivalents and Short-Term Investments | 7.57B | 6.49B | 5.91B | 5.05B | 4.21B |
| Total Debt | 335.05M | 346.53M | 301.33M | 7.44M | 14.91M |
| Total Liabilities | 2.72B | 2.57B | 2.54B | 1.85B | 1.30B |
| Stockholders Equity | 8.07B | 7.47B | 7.03B | 6.38B | 5.90B |
Cash Flow | |||||
| Free Cash Flow | 974.13M | 823.02M | 788.31M | 980.21M | 609.52M |
| Operating Cash Flow | 1.17B | 963.13M | 932.63M | 1.11B | 703.15M |
| Investing Cash Flow | 222.03M | -272.11M | -49.54M | -45.42M | 395.01M |
| Financing Cash Flow | -375.01M | -392.48M | -26.74M | -250.04M | -828.93M |
China Shineway Pharmaceutical Group Limited Technical Analysis
Neutral
8.52
Price Trends
8.06
Positive
8.38
Negative
8.52
Negative
Market Momentum
0.04
Negative
51.58
Neutral
38.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2877, the sentiment is Neutral. The current price of 8.52 is above the 20-day moving average (MA) of 8.13, above the 50-day MA of 8.06, and above the 200-day MA of 8.52, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 38.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2877.
China Shineway Pharmaceutical Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$6.19B | 6.83 | 9.81% | 17.17% | -17.74% | 1.12% | |
70 Outperform | HK$16.58B | 26.03 | 3.09% | 3.53% | -12.86% | -83.10% | |
70 Outperform | HK$1.93B | 6.49 | 13.26% | 9.23% | -0.47% | -0.40% | |
60 Neutral | HK$17.36B | 15.44 | 6.61% | 3.41% | 7.35% | -45.49% | |
53 Neutral | HK$6.72B | -5.53 | -4.98% | 0.26% | -15.80% | -298.94% | |
52 Neutral | HK$8.80B | 43.66 | 4.10% | 3.03% | 4.81% | -48.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2877
China Shineway Pharmaceutical Group Limited
8.39
0.08
1.01%
HK:3933
The United Laboratories International Holdings
8.46
-7.81
-48.00%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.34
-0.84
-38.48%
HK:2633
Jacobson Pharma Corporation Limited
0.98
-0.43
-30.69%
HK:0512
Grand Pharmaceutical Group Limited
4.95
-4.15
-45.57%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.69
-1.63
-22.27%
China Shineway Pharmaceutical Group Limited Corporate Events
China Shineway to Review Interim Results and Consider Dividend at August Board Meeting
Aug 17, 2026
China Shineway Pharmaceutical Group Limited has scheduled a board meeting for 27 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also consider the declaration of a dividend at the meeting...
China Shineway Wins Strong Shareholder Backing at 2026 AGM
May 28, 2026
China Shineway Pharmaceutical Group reported that shareholders approved all resolutions at its annual general meeting held on 28 May 2026, including adoption of the 2025 audited financial statements and re-election of key board members. The compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.